期刊
CURRENT OPINION IN CHEMICAL BIOLOGY
卷 12, 期 4, 页码 434-440出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2008.06.033
关键词
-
资金
- National Institutes of Health [CA127622]
- Life Sciences Research Foundation
With the recent US Food and Drug Administration approval of bortezomib (Velcade(R)) for the treatment of relapsed multiple myeloma, the proteasome has emerged as a new therapeutic target with diverse pathology. Drug discovery programs in academia and the pharmaceutical industry have developed a range of low nanomolar synthetic and natural inhibitors of the 20S proteasome core particle that have entered human clinical trials as significant anti-cancer and anti-inflammatory leads. Moreover, proteasome inhibitors continue to serve as valuable research tools in cellular biology through the elucidation of important biological processes associated with the ubiquitin-proteasome pathway of protein degradation. This review will highlight recent advances in the development and application of proteasome inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据